subunit is shared with the receptors for interle~kin-3'.~ and interleukin-5. ' High-affinity GMR are expressed on myeloid progenitors and mature myeloid cells including eosinophils,' mononuclear phagocyte^,^.^ and neutrophils.'"2 In these cells, GM-CSF induces proliferation, maturation, and/ or specific host defense functions, presumably through the high-affinity receptor (a-p c~m p l e x ) .~~'~"~ The GMR is found on acute and chronic myelogenous leukemia cells as well as certain immortalized hematopoietic cell lines.'-13 The receptor has also been found in several nonhematopoietic tissues, including normal placenta,'.' oligodendrocyte^,'^ and endothelial ~el1s.l~ The physiologic function of the GMR in these cells is unknown. GMR are also found on some malignant cells, including and small-cell carcinoma of the lung cell lines." There is evidence that GM-CSF may have proliferative effects on some tumor cell lines, as well as normal bone marrow fibroblast precursors and simian virus 40-transformed marrow stromal ~ells.''~'~ It was believed that GM-CSF signalling required both aand &receptor subunits2'"'; however, we recently showed that the isolated a subunit is capable of transmitting a signal for stimulation of glucose transport. 22 We studied human melanoma cell lines to determine whether GM-CSF can signal for glucose uptake in neoplastic nonhematopoietic cells that exhibit low-affinity binding of GM-CSF. We report that melanoma cell lines that exhibit low-affinity GM-CSF binding can increase glucose uptake in response to GM-CSF. One of the melanoma cell lines that contained a-subunit mRNA and responded to GM-CSF did not contain any psubunit mRNA. These findings indicate a metabolic function for the GMR expressed on neoplastic melanocytes. 3.44 and 1-5 of SK-MEL-131, and SK-MEL-188 cells expressed receptors with a dissociation constant (kd) for GM-CSF in the following ranges: 0.7 to 0.8, 1.2 to 1.8, and 0.4 to 0.8 nmol/L, respectively. GM-CSF stimulated glucose uptake in four of the melanoma cell lines expressing the a subunit, presumably through facilitative glucose transporters, as uptake was blocked by cytochalasin B but not cytochalasin E. Stimulation of glucose uptake was transient, with maximum stimulation occurring at approximately 30 minutes in the presence of 1 nmol/L GM-CSF. GM-CSF stimulated glucose uptake 1.4-to 2.0-fold but did not stimulate cell proliferation. These results suggest a metabolic role for the low-affinity GMR in melanoma cell lines and indicate that the (Y subunit of the GMR can signal for increased glucose uptake in nonhematopoietic tumor cells.
0 1995 by The American Society of Hematology.
MATERIALS AND METHODS
Melanoma cell lines SK-MEL-131 (clone 1-5), SK-MEL-131 (clone 3.44), SK-MEL-188, SK-MEL-23, SK-MEL-22, SK-MEL-22A, and SK-MEL-29 were grown in RPM1 1640 supplemented with 10% fetal calf ~e r u m . *~.~~ HL-60 and Moi'e myeloid leukemia cells and human T-cell lymphotropic virus type II (HTLV-11)-transformed J-RN T lymphoblasts were maintained in Iscove's modified Dulbecco's medium (IMDM). Cell viability was greater than 95%, as determined by trypan blue exclusion, and variance in cell number was less than 20%. Cells were treated with recombinant human GM-CSF (a gift from Amgen, Inc, Thousand Oaks, CA) as indicated in the figure legends.
A reverse transcription polymerase chain reaction (RT-PCR) assay was used to detect mRNA encoding the a and p subunits of the GMR. Total RNA was isolated from melanoma cells using RNAzol B (Biotecx, Houston, TX 1390-1410) .'~'~7 The 3' PCR primer was end-labeled with "P, and each was present at 6 nglyL. Two-step PCR was performed at 94°C for I minute and 65°C for 2 minutes for 35 cycles. Product ( 5 pL) was electrophoresed on a 5% acrylamide gel at 1 0 0 V for 4 hours. Dried gels were exposed for autoradiography. Because the a-subunit primers spanned the tt'dIXmembrane exon, the membrane-bound and soluble subunits could be resolved by gel electrophoresis based on the size difference of their PCR products resulting from the presence or absence of the transmembrane exon." Electrophoretic migration was consistent with the predicted sizes of the products (membranebound a subunit, 370 bp; soluble a subunit, 273 bp; p subunit, S72 bp). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal standard as described previo~sly.~~ This RT-PCR procedure has been shown to be quantitative and can detect fewer than SO a-subunit mRNA molecules per I O 5 cells."" Uptake of 2-deoxy-D-glucose (DOG) was measured as described previously.'7~'x Cells were treated at 25°C with RPMI 1640 lacking glucose, tyrosine, histidine, tryptophan, nicotinamide, and paraaminobenzoic acid and containing various concentrations of GM-CSF (modified RPMI) for the periods of time indicated. Uptake of [ 1. The dissociation constant (kd) of GM-CSF binding was determined by Scatchard analysis.",'' Cells were incubated in the presence of "'I-GM-CSF (New England Nuclear) for 4 hours at 4°C. washed three times with ice-cold PBS, solubilized as above, and counted in a gamma counter. Proliferation assays were performed in the presence and absence of 10% fetal calf serum. Thymidine incorporation was performed as described'"'" using subconfluent monolayers of cells treated with GM-CSF for 8 hours before pulsing with [methylL'H] thymidine (New England Nuclear) for 16 hours. Total GM-CSF treatment time was 24 hours. Cells were washed with PBS, solubilized in 0.03% SDS, extracted with trichloroacetic acid, applied to Whatman (Clifton, NJ) glass fiber filters, and counted for radioactivity.
RESULTS
Melanoma cell line expression of the GMR a-and psubunit mRNA. To analyze GMR in melanoma cell lines, the abundance of a-and P-subunit mRNA was determined by RT-PCR using glyceraldehyde-3-phosphate dehydrogenase mRNA to control for differences in RNA extraction and cDNA synthesis. Of seven melanoma cell lines tested, six contained a-subunit mRNA species ( Melanoma cells thut express a-subunit mRNA hind GM-CSF with low uflnity. We determined the binding affinity of melanoma cells for GM-CSF and compared it with that of Mo7e cells. Binding studies (Fig 2A) showed that clone 3.44, clone 1-5, and SK-MEL-188 cells, which express different levels of a-subunit mRNA species, bound GM-CSF at concentrations as low as 0.5 nmol/L, whereas SK-MEL-29 cells, which contained no a-subunit mRNA, had no GM- (Fig 2A) . Scatchard analysis (Fig 2B) of the data shown in Fig 2A indicated To test the function of GMR in melanoma cells, we examined changes in glucose uptake in response to GM-CSF treatment. Glucose uptake studies indicated that all seven cell lines had a remarkable ability to accumulate DOG (Fig 3,  panels A through F, and data not shown). There was no evidence of a relationship between the ability of the cells to accumulate DOG and the presence of the a-subunit mRNA. Cytochalasin B, an inhibitor of facilitative glucose transporters" but not its inactive analog, cytochalasin E, inhibited DOG uptake in all seven cell lines (Fig 3A through F , and data not shown), indicating the direct role of facilitative glucose transporters in mediating glucose uptake.
GM-CSF dose-response data, obtained after 20 minutes
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of treatment in clone 3.44 cells, showed that the greatest induction of DOG accumulation occurred with 1 nmol/L GM-CSF (1.8-fold increase), while 3 nmol/L GM-CSF produced a 1.6-fold increase (Fig 4) . Smaller increases in stimulation of DOG uptake were seen with as little as 0.03 nmol/ L GM-CSF, with a half-maximal effect observed at approximately 0.05 nmol/L. SK-MEL-29 cells, which lack an (Y subunit, did not show any increase in DOG uptake when treated with GM-CSF (Fig 4) . Cytochalasin B inhibited all DOG uptake in clone 3.44 cells treated with GM-CSF.
The effect of GM-CSF treatment time on DOG accumulation in four melanoma cell lines is shown in Fig 5. (Fig 5A) , twofold in clone 3.44 cells (Fig 5B) , 1.4-fold in SK-MEL-22A cells (Fig X ) , and 1 S-fold in SK-MEL-I 88 cells (Fig 5D) . After 30 minutes, increases in DOG uptake were less marked, and there was no effect after 1 hour. GM-CSF had no effect on SK-MEL-29 cells, which exhibit neither a-subunit mRNA expression nor GM-CSF binding, or on SK-MEL-23 cells, which contain small amounts of asubunit mRNA but do not demonstrate GM-CSF binding (data not shown). which all show increased DOG uptake in response to GM-CSF, did not show an increase in proliferation as measured by cell number when treated with GM-CSF (0.1, 1, or 10 nmol/L) in the presence or absence of serum (data not shown). In addition, SK-MEL-29 melanoma cells, which do not contain detectable a-subunit mRNA or show GM-CSF binding, did not proliferate in response to GM-CSF (data not shown). Incorporation of 3H-thymidine into clone 3.44 cells was also unaffected by GM-CSF treatment (data not shown).
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DISCUSSION
The presence of GMR on nonhematopoietic cells suggests a physiologic role for this hematopoietic cytokine outside of the blood-forming system. The role of GM-CSF in the function of placenta, endothelium, and neural tissue (oligodendrocytes) is ~n k n o w n . '~'~~" From a clinical perspective, there has been concern that some of the toxic effects of GM-CSF are due to interaction with nonhematopoietic cells as well as the potential ability of GM-CSF to stimulate tumor cell growth. Although no direct evidence for stimulation of tumor growth has been forthcoming in patients, in vitro observations suggest that some nonhematopoietic tumor cells might be responsive to GM-CSF.17,19,'2"6 Some of the proposed interactions of GM-CSF with tumor cells involve differentiation or altered f~n c t i o n .~'~~~~~~ The melanoma cell has presented a particular puzzle with regard to understanding GM-CSF interaction with nonhematopoietic cells in that it often expresses low-affinity GMR.I6 It is known that the highaffinity receptor (composed of a and , B subunits) is required for GM-CSF signalling for proliferative and functional responses in hematopoietic cells and that such signalling involves a protein kinase ~a s c a d e .~~~~'~'~~' * Recently, we demonstrated that the isolated a subunit of the GMR could signal for increased glucose transport through glucose transporters without inducing protein tyrosine phosphorylation.22 As lowaffinity receptors are found on melanoma cell lines and on a fresh melanoma tumor,16 we analyzed melanoma cell lines for the expression of the a and , B subunit of the GMR and assessed the ability of the GMR to cause changes in glucose uptake.
Melanoma cells that exhibited low-affinity GM-CSF binding (six of seven cell lines) expressed mRNA coding for the a subunit but little or no &subunit mRNA. There was a general correlation between the amount of low-affinity binding and steady state abundance of a-subunit mRNA. In addition, cells that did not contain a-subunit mRNA (SK-MEL-29) showed no binding of GM-CSF. In cells expressing the a subunit, GM-CSF induced a 1.4-to 2.0-fold increase in ~-glucose uptake. Maximum glucose uptake occurred at about 30 minutes. Thus, the low-affinity GMR expressed by human melanoma cells are functional with regard to signalling for glucose transport. There was no effect of GM-CSF on cell proliferation. Melanoma cells exhibited only low-affinity GM-CSF binding, a result consistent with the observation that these cells expressed only trace quantities of @-subunit mRNA. The dose-response studies showed that half-maximal stimulation of DOG uptake occurred at concentrations of GM-CSF that were less than 0.1 nmoVL; however, similar concentrations of GM-CSF were effective in Xenopus oocytes expressing only the isolated a subunit." Thus, the ability of the a subunit of the receptor to signal for glucose uptake when concentrations of GM-CSF are well below its kd appears to be an intrinsic property of the receptor. Other members of the family of cytokine receptors that lack intrinsic kinase activity also have been shown to be responsive to ligand concentrations below their kd.22,39-41 Although PCR analysis of the &subunit mRNA showed a weak signal in some cells after 35 cycles of PCR, the cells expressing trace amounts of mRNA for the @ subunit apparently do not make meaningful quantities of @-subunit protein, as there was no high-affinity binding.3" The amount of @-subunit mRNA present in the melanoma cells was at least four orders of magnitude less than that seen in hematopoietic cells that express high-affinity receptors. Clone 3.44 cells had no detectable @-subunit mRNA but relatively large quantities of the a subunit, and the kd of GM-CSF binding and induction of DOG accumulation by GM-CSF were similar to those in cells expressing trace levels of the @-subunit mRNA. These observations suggest that the increase in DOG accumulation induced by GM-CSF in these melanoma cells is mediated by the a subunit.
There was a correlation between the abundance of asubunit mRNA and the stage of differentiation of the melanoma cell lines. PCR analysis for GMR mRNA species was conducted in a quantitative manner and allowed for assessment of the membrane-bound and the soluble isoforms of a subunit. We and other investigators have identified a GMR a-subunit isoform lacking the transmembrane domain.2s,d2.43 We cloned this isoform and expressed it in heterologous cells, showing that it was secreted by the cells into the medium where it bound ligand at low affinity." The soluble subunit appears to arise by differential splicing, but its function is unIt has been difficult to understand how binding of ligand in the pericellular milieu at low affinity could biologically relate to the central hematopoietic role of GM-CSF acting through the high-affinity receptor on hematopoietic precursor cells. The discovery that the isolated a subunit can signal for glucose uptake provides a potential means for understanding a competitive role for the soluble isoform." Some of the melanoma cells express both the membranebound and the soluble isoform of the a subunit of the GMR. Under these circumstances, the soluble subunit could be envisioned as playing an inhibitory role with regard to competing for ligand in the extracellular milieu.
The demonstration of GM-CSF signalling for glucose up-
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2.0 a i take in melanoma cells indicates a potential metabolic role for GM-CSF in this tumor's biology. The results with cytochalasins B and E suggest that GM-CSF stimulates glucose uptake through facilitative glucose transporters, which cornprise a family of proteins that may have multifunctional transport a~t i v i t y .~~,~' -~' For example, we showed that dehydroascorbic acid is transported by glucose transporters:' and other investigators have suggested that they may transport other molecules as ell.^'.^^ The GM-CSF modulation of glucose uptake in melanoma cells, therefore, implies that cytokines could have a range of metabolic effects on tumor cells bearing cognate receptors. These findings provide new insights into the biology of the melanoma cell as well as the function of GMR in nonhematopoietic cells.
